Citation

Belanger A, Morris SB, Brostrom R, Yost D, Goswami N, Oxtoby M, Moore M, Westenhouse J, Barry PM, Shah NS. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 2019; 15.

Copyright

(Copyright © 2019)

DOI

10.1016/j.jctube.2019.01.005

PMID

unavailable

Abstract

The current tuberculosis (TB) case reporting system for the United States, the Report of Verified Case of TB (RVCT), has minimal capture of multidrug-resistant (MDR) TB treatment and adverse events. Data were abstracted in five states using the form for 13 MDR TB patients during 2012-2015. The Centers for Disease Control and Prevention Guidelines for Evaluating Public Health Surveillance Systems were used to evaluate attributes of the form. Unstructured interviews with pilot sites and stakeholders provided qualitative feedback. The form was acceptable, simple, stable, representative, and provided high-quality data but was not flexible or timely. For the 13 patients on whom data were collected, the median duration of treatment with an injectable medication was 216 days (IQR 203-252). Six (46%) patients reported a side effect requiring a medication change and eight (62%) had a side effect present at treatment completion. A standardized MDR TB supplemental surveillance form was well received by stakeholders whose feedback was critical to making modifications. The finalized form will be implemented nationally in 2020 and will provide MDR TB treatment and morbidity data in the United States to help ensure patients with MDR TB receive the most effective treatment regimens with the least toxic drugs. © 2019

Language: en

Keywords

United States; adult; Surveillance; human; female; male; aged; suicidal ideation; depression; suicide attempt; visual impairment; morbidity; controlled study; retrospective study; clinical article; priority journal; gastrointestinal symptom; isoniazid; tremor; side effect; heart disease; tinnitus; liver toxicity; peripheral neuropathy; hypothyroidism; Tuberculosis; tuberculostatic agent; cycloserine; vestibular disorder; Article; amikacin; heart ventricle arrhythmia; kidney dysfunction; treatment duration; ethambutol; pyrazinamide; rifampicin; linezolid; hearing impairment; levofloxacin; rifabutin; moxifloxacin; disease surveillance; streptomycin; aminosalicylic acid; ethionamide; multidrug resistant tuberculosis; capreomycin; Drug resistance; unstructured interview; bedaquiline; clofazimine; rifapentine